Back to search results

Sacituzumab Govitecan In TNBC

Abroad (travel likely)RecruitingPHASE2

Conditions

Invasive Breast Cancer · Triple Negative Breast Cancer · ER-Negative Breast Cancer · PR-Negative Breast Cancer · HER2-negative Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Sara Tolaney, MD, MPH) · 617-632-3800
    Contact: Principal Investigator (Sara Tolaney, MD, MPH)

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Laura Spring, MD) · LSPRING2@PARTNERS.ORG · 617-726-6500
    Contact: Principal Investigator (Laura Spring, MD)

  • Massachusetts General Hospital - North Shore Cancer Center, Danvers, Massachusetts, United States

    Contact: Study coordinator (Therese Mulvey, MD) · 978-882-6060
    Contact: Principal Investigator (Therese Mulvey, MD)

  • Massachusetts General Hospital at Newton-Wellesley Hospital, Newton, Massachusetts, United States

    Contact: Study coordinator (Amy Comander, MD) · 617-219-1230
    Contact: Principal Investigator (Amy Comander, MD)
Study leads

  • Laura Spring, MD

    Principal Investigator

    Massachusetts General Hospital

View source on ClinicalTrials.gov(opens in a new tab)